# Expanded Access Protocol of ZULRESSO™ (Brexanolone) Injection for Adult Patients With Postpartum Depression

> **NCT03924492** · — · APPROVED_FOR_MARKETING · sponsor: **Supernus Pharmaceuticals, Inc.**

## Conditions studied

- Postpartum Depression

## Interventions

- **DRUG:** ZULRESSO (brexanolone) injection

## Key facts

- **NCT ID:** NCT03924492
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03924492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03924492, "Expanded Access Protocol of ZULRESSO™ (Brexanolone) Injection for Adult Patients With Postpartum Depression". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT03924492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*